[1]陈晓旭,王光铭,刘万里,等.健脾利湿解毒方治疗慢性结肠炎脾虚湿毒证疗效研究[J].陕西中医,2024,(12):1640-1643,1648.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.011]
　CHEN Xiaoxu,WANG Guangming,LIU Wanli,et al.The clinical effect of Jianpi Lishi Jiedu decoction in treating chronic colitis of spleen deficiency and dampness-toxin syndrome[J].,2024,(12):1640-1643,1648.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.011]
点击复制

健脾利湿解毒方治疗慢性结肠炎脾虚湿毒证疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1640-1643,1648
栏目:
临床研究
出版日期:
2024-12-05

文章信息/Info

Title:
The clinical effect of Jianpi Lishi Jiedu decoction in treating chronic colitis of spleen deficiency and dampness-toxin syndrome
作者:
陈晓旭1; 王光铭1; 刘万里2; 吴 昊1
(1.南京中医药大学附属南京市中西医结合医院,江苏 南京 210014; 2.南京医科大学附属南京医院 南京市第一医院,江苏 南京 210006)
Author(s):
CHEN Xiaoxu; WANG Guangming; LIU Wanli; WU Hao
(The Nanjing University of Chinese Medicine Affiliated Nanjing Hospital of Integrated Chinese and Western Medicine,Nanjing 210014,China)
关键词:
慢性结肠炎;  脾虚湿毒证;  健脾利湿解毒方;  脑肠肽;  炎症因子;  粪便钙卫蛋白
Keywords:
Chronic colitis;  Spleen deficiency and dampness-toxin syndrome;  Jianpi Lishi Jiedu decoction;  Brain-gut peptide;  Inflammatory factor;  Fecal calprotectin
分类号:
R 574.62
DOI:
DOI:10.3969/j.issn.1000-7369.2024.12.011
文献标志码:
A
摘要:
目的:观察健脾利湿解毒方治疗慢性结肠炎脾虚湿毒证的临床疗效。方法:选取120例确诊为慢性结肠炎脾虚湿毒证的患者,采取随机数字表法分为观察组以及对照组,每组60例。对照组采取口服复方嗜酸乳杆菌片治疗,观察组在对照组治疗的基础上采取口服健脾利湿解毒方治疗,疗程均为3个月。治疗完成后比较两组治疗前后中医证候积分及脑肠肽[血管活性肠肽(VIP)、5-羟色胺(5-HT)、P物质(SP)、生长抑素(SS)]、炎症因子[C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-17(IL-17)]和粪便钙卫蛋白(FC)水平。比较两组总有效率及不良反应发生情况。结果:治疗后,观察组总有效率高于对照组(P<0.05); 治疗后,两组中医证候积分均较治疗前降低,组间相比,观察组水平更低(均P<0.05); 治疗后,两组VIP、5-HT、SP、SS、CRP、TNF-α、IL-17水平以及FC水平较治疗前降低,组间相比,观察组水平更低(均P<0.05)。两组均无不良反应。结论:健脾利湿解毒方可改善慢性结肠炎患者各项症状,抑制脑肠肽水平及炎性反应,且临床安全性高、无明显不良反应。
Abstract:
Objective:To observe the clinical effect of Jianpi Lishi Jiedu decoction in treating chronic colitis of dampness-toxin syndrome due to spleen deficiency.Methods:A total of 120 patients with spleen deficiency and dampness-toxicity syndrome of chronic colitis were selected,they were randomly divided into observation group and control group with 60 patients in each group.The control group was treated with compound Lactobacillus acidophilus tablet,and the observation group was treated with Jianpi Lishi Jiedu decoction on the basis of the treatment in the control group.The course of treatment was three months.After treatment,the TCM syndrome scores and the levels of brain-gut peptide [vasoactive intestinal peptide(VIP),5-hydroxytryptamine(5-HT),substance P(SP),somatostatin(SS)],inflammatory factors [C-reactive protein(CRP),tumor necrosis factor(TNF-α),interleukin-17(IL-17)] and fecal calprotectin(FC)were compared between the two groups.The total effective rate and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of observation group was higher than that of control group(P<0.05).After treatment,TCM syndrome scores of both groups were lower than before treatment,and the level of observation group was lower than control group(all P<0.05).After treatment,the levels of VIP,5-HT,SP,SS,CRP,TNF-α,IL-17 and FC in two groups were lower than before treatment,and the levels in observation group were lower than control group(all P<0.05).There were no adverse reactions in both groups.Conclusion:It can improve the symptoms of patients with chronic colitis,inhibit the level of brain-gut peptide and inflammatory response,and has high clinical safety and no obvious adverse reactions.

参考文献/References:

[1] STAVELY R,FRASER S,SHARMA S,et al.The onset and progression of chronic colitis parallels increased mucosal serotonin release via enterochromaffin cell hyperplasia and downregulation of the serotonin reuptake transporter[J].Inflamm Bowel Dis,2018,24(5):1021-1034.
[2] EUN-YOUNG K C,HENRY D A.Chronic colitis in biopsy samples:Is it inflammatory bowel disease or something else?[J].Surg Pathol Clin,2017,10(4):841-861.
[3] 陈熠.百年百名老中医内科专家——陈苏生[M].北京:中国中医药出版社,2014:150.
[4] 张宪波,刘月皎,陈云峰.粪便钙卫蛋白在肠易激综合征和炎症性肠病鉴别诊断中的意义分析[J].现代检验医学杂志,2021,36(1):124-127.
[5] 吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年?北京)[J].中国实用内科杂志,2018,38(9):796-813.
[6] 国家中医药管理局医政司.24个专业105个病种中医诊疗方案(合订本)[M].北京:人民卫生出版社,2011:443.
[7] 国家食品药品监督管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:369-371.
[8] 单永改,刘万里,吴昊.健脾利湿解毒方治疗大肠息肉内镜下治疗术后脾虚湿毒证31例临床研究[J].江苏中医药,2022,54(8):45-49.
[9] 林俊儒,游荣荣,华云玮.健脾清肠汤对脓毒症腹泻患者肠道功能、炎症因子及乳酸的影响[J].中医药学报,2024,52(2):53-57.
[10] 江娟,李静,夏可,等.反复肺炎患儿肠道菌群与免疫功能指标变化及相关性研究[J].陕西医学杂志,2023,52(9):1200-1203.
[11] 冯永波,周忠海,高玉华,等.甘草泻心汤治疗溃疡性结肠炎的疗效及患者肠道菌群、炎症免疫细胞因子变化研究[J].吉林中医药,2023,43(8):940-944.
[12] 王泽惠,陈天,彭云花,等.清热愈疡汤治疗溃疡性结肠炎对患者肠道菌群紊乱和改善炎症效果的组方分析[J].吉林中医药,2024,44(4):448-452.
[13] 周琼阁,王凯,席作武,等.基于肠道微环境探讨中医药防治溃疡性结肠炎的机制[J].中国实验方剂学杂志,2023,29(7):222-229.
[14] 许江华.参苓白术散加减治疗慢性结肠炎患者的临床分析[J].北方药学,2021,18(6):77-78.
[15] 沈金鳌.杂病源流犀烛[M].北京:人民卫生出版社,2006:121.
[16] 黄宫绣.本草求真[M].北京:中国中医药出版社,1997:188.
[17] 安琦,芦希艳,王伟,等.抗激护肠方治疗腹泻型肠易激综合征临床研究[J].陕西中医,2023,44(10):1382-1386.
[18] 汪昂.本草备要[M].北京:人民卫生出版社,2005:43.
[19] 严洁,施雯,洪炜.得配本草[M].北京:人民卫生出版社,2007:108.
[20] 吴仪洛.本草从新[M].北京:中国中医药出版社,2013:28.
[21] 张媛婷,胡宗仁,陈新宇.陈新宇教授治疗溃疡性结肠炎经验[J].陕西中医,2022,43(8):1102-1105.
[22] 李力恒,陈昌瑾,胡晓阳,等.党参的化学成分及药理作用研究进展[J].中医药学报,2023,51(3):112-115.
[23] 蒯欢欢,于骏娣,李灿涛,等.基于网络药理学探讨土茯苓防治炎症性肠病的作用机制[J].现代药物与临床,2023,38(6):1352-1359.
[24] 陈琼,梅红,王宝香,等.柚皮素对溃疡性结肠炎小鼠肠组织中miR-30a-3p/PTEN信号轴表达的影响[J].西部医学,2022,34(7):960-965.
[25] 程伟伟,王玲,冯玉灵,等.参苓白术散对脾虚型小儿泄泻胃电图的影响[J].中国实验方剂学杂志,2022,28(2):154-158.
[26] 郝梦超,姚甜,刘二奴,等.忍冬中的活性成分及其药理活性研究现状[J].药物分析杂志,2024,44(2):195-213.
[27] 白鹏飞,张艳君,李敏.荆芥连翘汤加减从肺论治溃疡性结肠炎疗效及对患者肠黏膜屏障功能、免疫调节、氧化应激指标的影响[J].陕西中医,2020,41(7):897-900.
[28] 苏允思,张秀云,郭庆梅.白薇化学成分及药理作用研究进展[J].中华中医药学刊,2021,39(11):171-177.
[29] 张续,赵莉平,安荣.肠易激综合征生物标志物研究进展[J].陕西医学杂志,2022,51(8):1038-1041.

备注/Memo

备注/Memo:
基金项目:江苏省中医药科技发展计划项目(YB2020030); 南京市医学科技发展重点项目(ZKX21057)
更新日期/Last Update: 2024-12-05